Literature DB >> 6402991

Serological markers in progressive systemic sclerosis: clinical correlations.

L J Catoggio, R M Bernstein, C M Black, G R Hughes, P J Maddison.   

Abstract

The relation between clinical and serological findings was studied in 75 patients with definite progressive systemic sclerosis (PSS). Antinuclear antibodies were detected by indirect immunofluorescence in 95% of the patients by means of HEp-2 cells. The centromere pattern was observed in 50% of the patients with calcinosis, Raynaud's phenomenon, oesophageal dysmotility, sclerodactyly, and telangiectasia (CREST) and only 7% of the group with diffuse disease. Precipitating antibodies to nuclear and cytoplasmic antigens were detected by immunodiffusion in 53% of the patients and identified as anti Scl-70 in 16 (21%). We confirmed that autoantibodies are very frequent in PSS but varied in specificity. A combination of immunodiffusion and indirect immunofluorescence was useful in detecting antibodies characteristic of PSS (i.e., anti-Scl-70 and anticentromere) in 51% of these patients. Anticentromere antibody has a high specificity for CREST and identifies patients with less severe disease (i.e., more prolonged course and less involvement of internal organs). Anti-Scl-70 was associated with a high frequency of lung involvement.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6402991      PMCID: PMC1001054          DOI: 10.1136/ard.42.1.23

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  12 in total

1.  Differentiation and characterization of autoantibodies and their antigens in Sjögren's syndrome.

Authors:  M A Alspaugh; N Talal; E M Tan
Journal:  Arthritis Rheum       Date:  1976 Mar-Apr

2.  Immunological detection of nucleic acids and antibodies to nucleic acids and nuclear antigens by counterimmunoelectrophoresis.

Authors:  P H Schur; D DeAngelis; J M Jackson
Journal:  Clin Exp Immunol       Date:  1974-05       Impact factor: 4.330

3.  Characterization of a soluble nuclear ribonucleoprotein antigen reactive with SLE sera.

Authors:  M Mattioli; M Reichlin
Journal:  J Immunol       Date:  1971-11       Impact factor: 5.422

4.  Antinucleolar antibodies. Their frequency and diagnostic association.

Authors:  R F Ritchie
Journal:  N Engl J Med       Date:  1970-05-21       Impact factor: 91.245

5.  Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Characterization of the Jo-1 antibody system.

Authors:  M Nishikai; M Reichlin
Journal:  Arthritis Rheum       Date:  1980-08

6.  Immunochemical characterization of the anti-RNA antibodies found in scleroderma and systemic lupus erythematosus. I. Differences in reactivity with Poly (U) and Poly-(A) Poly (U).

Authors:  D Alarcón-Segovia; E Fishbein
Journal:  J Immunol       Date:  1975-07       Impact factor: 5.422

7.  Autoantibody to centromere (kinetochore) in scleroderma sera.

Authors:  Y Moroi; C Peebles; M J Fritzler; J Steigerwald; E M Tan
Journal:  Proc Natl Acad Sci U S A       Date:  1980-03       Impact factor: 11.205

8.  The CREST syndrome: a distinct serologic entity with anticentromere antibodies.

Authors:  M J Fritzler; T D Kinsella
Journal:  Am J Med       Date:  1980-10       Impact factor: 4.965

9.  Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome.

Authors:  E M Tan; G P Rodnan; I Garcia; Y Moroi; M J Fritzler; C Peebles
Journal:  Arthritis Rheum       Date:  1980-06

10.  Uracil-specific anti-R.N.A. antibodies in scleroderma.

Authors:  D Alarcón-Segovia; E Fishbein; E García-Ortigoza; S Estrada-Parra
Journal:  Lancet       Date:  1975-02-15       Impact factor: 79.321

View more
  46 in total

1.  Systemic sclerosis in the elderly.

Authors:  L Czirják; Z Nagy; G Szegedi
Journal:  Clin Rheumatol       Date:  1992-12       Impact factor: 2.980

Review 2.  Anti-centromere antibodies (ACA).

Authors:  C G Kallenberg
Journal:  Clin Rheumatol       Date:  1990-03       Impact factor: 2.980

Review 3.  Rheumatology.

Authors:  R A Asherson; R Cervera; D P D'Cruz; G R Hughes
Journal:  Postgrad Med J       Date:  1991-02       Impact factor: 2.401

4.  Autoantibody profile in systemic sclerosis as a marker for esophageal and other organ involvement in Turkish populations.

Authors:  Nurten Savas; Ulku Dagli; Esin Ertugrul; Sedef Kuran; Burhan Sahin
Journal:  Dig Dis Sci       Date:  2007-03-28       Impact factor: 3.199

Review 5.  Utility of serologic testing in the diagnosis of noninfectious pulmonary disorders.

Authors:  R H White; J A Golden
Journal:  Clin Rev Allergy       Date:  1990 Summer-Fall

6.  IgM, IgG, and IgA anti-DNA topoisomerase I antibodies in systemic sclerosis.

Authors:  Erasmo Martínez-Cordero; Alejandro Padilla Trejo; Diana E Aguilar León
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

7.  Antireticulin antibody in systemic sclerosis.

Authors:  T Mahmud; M Peakman; G Senaldi; A McWhirter; C M Black; D Vergani
Journal:  Ann Rheum Dis       Date:  1990-03       Impact factor: 19.103

8.  Antikinetochore and antitopoisomerase I antibodies in systemic scleroderma: comparative study using immunoblotted recombinant antigens, immunofluorescence, and double immunodiffusion.

Authors:  M Jarzabek-Chorzelska; M Blaszczyk; Z Kolacinska-Strasz; T Chorzelski; S Jabłońska; G G Maul
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

9.  Sjögren's in adult Still's disease?

Authors:  D M Sanchez Loria; M J Moreno Alvarez; H A Barceló; L J Catoggio; J A Maldonado Cocco
Journal:  Clin Rheumatol       Date:  1996-03       Impact factor: 2.980

10.  Anti-centromere antibodies (ACA) in systemic sclerosis patients and their relatives: a serological and HLA study.

Authors:  N J McHugh; J Whyte; C Artlett; D C Briggs; C O Stephens; N J Olsen; N G Gusseva; P J Maddison; C M Black; K Welsh
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.